Viral Vector Development And Manufacturing Services

Viral vector manufacturing for cell and gene therapies involves highly specialized, multi-step processes that present challenges across the entire product lifecycle. Developers must navigate critical decisions around platform selection, scalability, product quality, regulatory compliance, and CMC strategy — all while working to maintain timelines and control risk. Selecting the right production system, ensuring consistent vector performance, and establishing standardized, reproducible processes are essential to building a robust and inspection-ready development program.

Thermo Fisher Scientific is a global CDMO partner offering comprehensive support for the development, manufacture, and commercialization of viral vectors and cell- and gene-therapy–based vaccines. Our integrated, end-to-end capabilities span process and analytical development, process characterization and validation, clinical and commercial-scale manufacturing, in-process and release testing, and fill-finish services. Supported by a global network of manufacturing sites, established clinical supply chain infrastructure, and deep technical and regulatory expertise in viral vectors, we provide a coordinated approach designed to reduce complexity, mitigate risk, and accelerate your therapy’s journey from development to market.